Federal Oversight Group Has Complaints But Says Yes To CRISPR Trial
By Alex Lash,
Xconomy
| 06. 21. 2016
Despite worries about conflict of interest, a National Institutes of Health committee that oversees the use of gene therapy and other cutting edge biomedical technologies voted today to let researchers move ahead with a landmark clinical trial. Depending on timing, it could be the first to use the gene editing system CRISPR-Cas9 in a human treatment.
There are still hurdles. The University of Pennsylvania School of Medicine team, led by high profile cancer researcher Carl June and funded by billionaire Sean Parker’s new cancer institute, must get a green light from the FDA, according to NIH regulations. It’s not clear when Penn hopes to start a trial, which would be small and designed to evaluate the safety of an experimental treatment for several types of cancer.
[Updated with Penn Medicine statement.] In response to questions about the conflict of interest and a timeline for the trial, a spokeswoman emailed a statement that said Penn Medicine “was pleased” by the vote and looks forward to presenting the trial for FDA review. It did not address the conflict or...
Related Articles
By Azeen Ghorayshi and Sarah Kliff, The New York Times | 08.12.2024
An emerging movement against in vitro fertilization is driving some doctors and patients in red states to move or destroy frozen embryos.
The embryo migration is most striking in Alabama, where the State Supreme Court ruled in February that embryos...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...
By Amanda Becker and Shefali Luthra, The 19th | 07.08.2024
Image by Duke University Archives from Flickr
Republicans have adopted a slate of policy positions ahead of next week’s convention that does not call for a federal legislative abortion ban, but opens the door to establishing fetal personhood.
The Republican...
By Beth Duff-Brown, Stanford Institute for Economic Policy Research | 07.12.2024
The debate over in vitro fertilization (IVF) has become a hot-button policy and political issue, despite the medical procedure to help people become pregnant having been mainstream in the United States for nearly half a century.
The Alabama Supreme Court ...
